braf ve1 Search Results


braf v600e (clone ve1) antibody  (Merck KGaA)
90
Merck KGaA braf v600e (clone ve1) antibody
Braf V600e (Clone Ve1) Antibody, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/braf v600e (clone ve1) antibody/product/Merck KGaA
Average 90 stars, based on 1 article reviews
braf v600e (clone ve1) antibody - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
anti-human braf v600e antibody ve1  (AbCys s a)
90
AbCys s a anti-human braf v600e antibody ve1
Anti Human Braf V600e Antibody Ve1, supplied by AbCys s a, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-human braf v600e antibody ve1/product/AbCys s a
Average 90 stars, based on 1 article reviews
anti-human braf v600e antibody ve1 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
anti-braf v600e (ve1) mouse monoclonal antibody  (OptiView Technologies)
90
OptiView Technologies anti-braf v600e (ve1) mouse monoclonal antibody
Anti Braf V600e (Ve1) Mouse Monoclonal Antibody, supplied by OptiView Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-braf v600e (ve1) mouse monoclonal antibody/product/OptiView Technologies
Average 90 stars, based on 1 article reviews
anti-braf v600e (ve1) mouse monoclonal antibody - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
ahnak2 galectin 3 braf v600e  (Galectin Therapeutics)
86
Galectin Therapeutics ahnak2 galectin 3 braf v600e
RT-qPCR experiments to explore the expression of <t>AHNAK2</t> in 10 PTC tissues and 10 adjacent tissues
Ahnak2 Galectin 3 Braf V600e, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ahnak2 galectin 3 braf v600e/product/Galectin Therapeutics
Average 86 stars, based on 1 article reviews
ahnak2 galectin 3 braf v600e - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
braf v600e ve1  (DCS Innovative Diagnostik-Systeme)
90
DCS Innovative Diagnostik-Systeme braf v600e ve1
RT-qPCR experiments to explore the expression of <t>AHNAK2</t> in 10 PTC tissues and 10 adjacent tissues
Braf V600e Ve1, supplied by DCS Innovative Diagnostik-Systeme, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/braf v600e ve1/product/DCS Innovative Diagnostik-Systeme
Average 90 stars, based on 1 article reviews
braf v600e ve1 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


RT-qPCR experiments to explore the expression of AHNAK2 in 10 PTC tissues and 10 adjacent tissues

Journal: Diagnostic Pathology

Article Title: Diagnostic value of AHNAK2 immunohistochemical expression in papillary thyroid carcinoma: an immunohistochemical study

doi: 10.1186/s13000-025-01723-1

Figure Lengend Snippet: RT-qPCR experiments to explore the expression of AHNAK2 in 10 PTC tissues and 10 adjacent tissues

Article Snippet: AHNAK2 Galectin-3 BRAF V600E , 93.9 , 96.3 , 97.6 , 95.1 , 98.7 , 0.992(0.977–0.996) , < 0.001.

Techniques: Quantitative RT-PCR, Expressing

Expression of different immunohistochemical markers in thyroid tumors. A1: PTC (H&E, × 200); A2: NIFTP (H&E, × 200); A3: FTC (H&E, × 200); A4: FA (H&E, × 200); A5: LT (H&E, × 200); A6: (H&E, × 200); B1: Diffuse positive staining of AHNAK2 in PTC cell membranes and cytoplasm (AHNAK2, × 200); B2: Focal cell membrane positivity of AHNAK2 in NIFTP cell membranes (AHNAK2, × 200); B3: Focal positive staining of AHNAK2 in FTC cell membranes (AHNAK2, × 200); B4: Negative staining of AHNAK2 in FA (AHNAK2, × 200); B5: Negative staining of AHNAK2 in lymphocytic thyroiditis (AHNAK2, × 200); B6: No expression of AHNAK2 in normal thyroid tissue (AHNAK2, × 200); C1: Diffuse cytoplasmic positivity of galectin-3 in PTC (galectin-3, × 200); C2: focal positivity of galectin-3 in NIFTP (galectin-3, × 200); C3: negative reaction of galectin-3 in FTC (galectin-3, × 200); C4: Negative staining of galectin-3 in FA, with staining of histocyte (galectin-3, × 200); C5: Negative reaction of galectin-3 in lymphocytic thyroiditis (galectin-3, × 200); C6: Negative staining of galectin-3 in normal thyroid tissue (galectin-3, × 200); D1: Diffuse cytoplasmic strong positivity of BRAF V600E in PTC (BRAF V600E, × 200); D2-6: Negative staining of BRAF V600E in NIFTP, FTC, FA, lymphocytic thyroiditis and normal thyroid tissue, with non-specific adsorption in the follicular lumen. (BRAF V600E, × 200); E1-4: Focal marginal staining of HBME-1 in PTC, NIFTP, FTC, FA (HBME-1, × 200); E5-6: No expression of HBME-1 in lymphocytic thyroiditis and normal thyroid tissue (HBME-1, × 200); F1-5: Diffuse membrane staining of CK19 in PTC, NIFTP, FTC, FA, and lymphocytic thyroiditis (CK19, × 200); F6: Diffuse staining of CK19 in surrounding normal thyroid tissue, with lower staining intensity than tumor tissue (CK19, × 200); G1-4: Diffuse nuclear staining of cyclin-D1 in PTC, NIFTP, FTC, and FA (cyclin-D1, × 200); G5: Focal nuclear staining of cyclin-D1 in lymphocytic thyroiditis (cyclin-D1, × 200); G6: Point-like nuclear staining of cyclin-D1 in surrounding thyroid tissue (cyclin-D1, × 200); H1: Mostly membrane positivity of TPO in PTC (TPO , × 200); H2-6: Diffuse membrane positivity of TPO in PTC (TPO , × 200); I1: Partial membrane positivity of CD56 in PTC (CD56 , × 200); I2: Negative reaction of CD56 in NIFTP (CD56 , × 200); I3: Focal membrane staining of CD56 in FTC (CD56 , × 200); I4-6: Diffuse membrane staining of CD56 in FA, lymphocytic thyroiditis, and normal thyroid tissue (CD56 , × 200)

Journal: Diagnostic Pathology

Article Title: Diagnostic value of AHNAK2 immunohistochemical expression in papillary thyroid carcinoma: an immunohistochemical study

doi: 10.1186/s13000-025-01723-1

Figure Lengend Snippet: Expression of different immunohistochemical markers in thyroid tumors. A1: PTC (H&E, × 200); A2: NIFTP (H&E, × 200); A3: FTC (H&E, × 200); A4: FA (H&E, × 200); A5: LT (H&E, × 200); A6: (H&E, × 200); B1: Diffuse positive staining of AHNAK2 in PTC cell membranes and cytoplasm (AHNAK2, × 200); B2: Focal cell membrane positivity of AHNAK2 in NIFTP cell membranes (AHNAK2, × 200); B3: Focal positive staining of AHNAK2 in FTC cell membranes (AHNAK2, × 200); B4: Negative staining of AHNAK2 in FA (AHNAK2, × 200); B5: Negative staining of AHNAK2 in lymphocytic thyroiditis (AHNAK2, × 200); B6: No expression of AHNAK2 in normal thyroid tissue (AHNAK2, × 200); C1: Diffuse cytoplasmic positivity of galectin-3 in PTC (galectin-3, × 200); C2: focal positivity of galectin-3 in NIFTP (galectin-3, × 200); C3: negative reaction of galectin-3 in FTC (galectin-3, × 200); C4: Negative staining of galectin-3 in FA, with staining of histocyte (galectin-3, × 200); C5: Negative reaction of galectin-3 in lymphocytic thyroiditis (galectin-3, × 200); C6: Negative staining of galectin-3 in normal thyroid tissue (galectin-3, × 200); D1: Diffuse cytoplasmic strong positivity of BRAF V600E in PTC (BRAF V600E, × 200); D2-6: Negative staining of BRAF V600E in NIFTP, FTC, FA, lymphocytic thyroiditis and normal thyroid tissue, with non-specific adsorption in the follicular lumen. (BRAF V600E, × 200); E1-4: Focal marginal staining of HBME-1 in PTC, NIFTP, FTC, FA (HBME-1, × 200); E5-6: No expression of HBME-1 in lymphocytic thyroiditis and normal thyroid tissue (HBME-1, × 200); F1-5: Diffuse membrane staining of CK19 in PTC, NIFTP, FTC, FA, and lymphocytic thyroiditis (CK19, × 200); F6: Diffuse staining of CK19 in surrounding normal thyroid tissue, with lower staining intensity than tumor tissue (CK19, × 200); G1-4: Diffuse nuclear staining of cyclin-D1 in PTC, NIFTP, FTC, and FA (cyclin-D1, × 200); G5: Focal nuclear staining of cyclin-D1 in lymphocytic thyroiditis (cyclin-D1, × 200); G6: Point-like nuclear staining of cyclin-D1 in surrounding thyroid tissue (cyclin-D1, × 200); H1: Mostly membrane positivity of TPO in PTC (TPO , × 200); H2-6: Diffuse membrane positivity of TPO in PTC (TPO , × 200); I1: Partial membrane positivity of CD56 in PTC (CD56 , × 200); I2: Negative reaction of CD56 in NIFTP (CD56 , × 200); I3: Focal membrane staining of CD56 in FTC (CD56 , × 200); I4-6: Diffuse membrane staining of CD56 in FA, lymphocytic thyroiditis, and normal thyroid tissue (CD56 , × 200)

Article Snippet: AHNAK2 Galectin-3 BRAF V600E , 93.9 , 96.3 , 97.6 , 95.1 , 98.7 , 0.992(0.977–0.996) , < 0.001.

Techniques: Expressing, Immunohistochemical staining, Staining, Membrane, Negative Staining, Adsorption

Receiver operating characteristic (ROC) curves of various immunohistochemical markers for distinguishing benign and malignant thyroid tumors (The areas under the curve (AUC) were as follows: AHNAK2=0.964; Galectin-3=0.935; BRAF=0.907; HBME-1=0.882; Cyclin-D1=0.776; CK19=0.752; CD56=0.053; TPO=0.004)

Journal: Diagnostic Pathology

Article Title: Diagnostic value of AHNAK2 immunohistochemical expression in papillary thyroid carcinoma: an immunohistochemical study

doi: 10.1186/s13000-025-01723-1

Figure Lengend Snippet: Receiver operating characteristic (ROC) curves of various immunohistochemical markers for distinguishing benign and malignant thyroid tumors (The areas under the curve (AUC) were as follows: AHNAK2=0.964; Galectin-3=0.935; BRAF=0.907; HBME-1=0.882; Cyclin-D1=0.776; CK19=0.752; CD56=0.053; TPO=0.004)

Article Snippet: AHNAK2 Galectin-3 BRAF V600E , 93.9 , 96.3 , 97.6 , 95.1 , 98.7 , 0.992(0.977–0.996) , < 0.001.

Techniques: Immunohistochemical staining

Positive distribution ranges of AHNAK2, galectin-3, and BRAF V600E in PTC. (The positive rate of AHNAK2, galectin-3, and BRAF V600E in PTC were 95%, 89.5%, and 82.4%, respectively. The diffuse positive rate were 59.1%, 68.6%, and 77.7%, respectively.)

Journal: Diagnostic Pathology

Article Title: Diagnostic value of AHNAK2 immunohistochemical expression in papillary thyroid carcinoma: an immunohistochemical study

doi: 10.1186/s13000-025-01723-1

Figure Lengend Snippet: Positive distribution ranges of AHNAK2, galectin-3, and BRAF V600E in PTC. (The positive rate of AHNAK2, galectin-3, and BRAF V600E in PTC were 95%, 89.5%, and 82.4%, respectively. The diffuse positive rate were 59.1%, 68.6%, and 77.7%, respectively.)

Article Snippet: AHNAK2 Galectin-3 BRAF V600E , 93.9 , 96.3 , 97.6 , 95.1 , 98.7 , 0.992(0.977–0.996) , < 0.001.

Techniques:

Positive status of the combination of AHNAK2, Galectin-3, and BRAF V600E in PTC. (222 cases were positive for all three markers.)

Journal: Diagnostic Pathology

Article Title: Diagnostic value of AHNAK2 immunohistochemical expression in papillary thyroid carcinoma: an immunohistochemical study

doi: 10.1186/s13000-025-01723-1

Figure Lengend Snippet: Positive status of the combination of AHNAK2, Galectin-3, and BRAF V600E in PTC. (222 cases were positive for all three markers.)

Article Snippet: AHNAK2 Galectin-3 BRAF V600E , 93.9 , 96.3 , 97.6 , 95.1 , 98.7 , 0.992(0.977–0.996) , < 0.001.

Techniques:

Positivity rates/ number of cases of the combination of AHNAK2, galectin-3, and BRAF V600E in PTC. (The positive rate of all three markers was 75.00%.)

Journal: Diagnostic Pathology

Article Title: Diagnostic value of AHNAK2 immunohistochemical expression in papillary thyroid carcinoma: an immunohistochemical study

doi: 10.1186/s13000-025-01723-1

Figure Lengend Snippet: Positivity rates/ number of cases of the combination of AHNAK2, galectin-3, and BRAF V600E in PTC. (The positive rate of all three markers was 75.00%.)

Article Snippet: AHNAK2 Galectin-3 BRAF V600E , 93.9 , 96.3 , 97.6 , 95.1 , 98.7 , 0.992(0.977–0.996) , < 0.001.

Techniques:

Receiver operating characteristic (ROC) curves for the combined diagnosis of benign and malignant thyroid tumors using three immunohistochemical markers. (The areas under the curve (AUC) were as follows: AHNAK2 or galectin-3 or BRAF V600E=0.992; AHNAK2 or BRAF V600E=0.989; AHNAK2 or galectin-3=0.986; galectin-3 or BRAF V600E=0.969）

Journal: Diagnostic Pathology

Article Title: Diagnostic value of AHNAK2 immunohistochemical expression in papillary thyroid carcinoma: an immunohistochemical study

doi: 10.1186/s13000-025-01723-1

Figure Lengend Snippet: Receiver operating characteristic (ROC) curves for the combined diagnosis of benign and malignant thyroid tumors using three immunohistochemical markers. (The areas under the curve (AUC) were as follows: AHNAK2 or galectin-3 or BRAF V600E=0.992; AHNAK2 or BRAF V600E=0.989; AHNAK2 or galectin-3=0.986; galectin-3 or BRAF V600E=0.969）

Article Snippet: AHNAK2 Galectin-3 BRAF V600E , 93.9 , 96.3 , 97.6 , 95.1 , 98.7 , 0.992(0.977–0.996) , < 0.001.

Techniques: Biomarker Discovery, Immunohistochemical staining